Apex Biotechnology (TPE:1733) Cyclically Adjusted Book per Share: NT$20.46 (As of Dec. 2025)


TPE:1733 Apex Biotechnology Corp TPE:1733
81 GF Score
Price NT$29.90
GF Value NT$30.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Apex Biotechnology Cyclically Adjusted Book per Share?

Apex Biotechnology TPE:1733 -0.17% 81 Cyclically Adjusted Book per Share is NT$20.46 as of Dec. 2025. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Apex Biotechnology's adjusted book value per share for the three months ended in Dec. 2025 was NT$18.707. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$20.46 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Apex Biotechnology's average Cyclically Adjusted Book Growth Rate was -0.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -0.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 1.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Apex Biotechnology was 2.70% per year. The lowest was -0.70% per year. And the median was 1.65% per year.

As of today (2026-07-08), Apex Biotechnology's current stock price is NT$29.90. Apex Biotechnology's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2025 was NT$20.46. Apex Biotechnology's Cyclically Adjusted PB Ratio of today is 1.46.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Apex Biotechnology was 1.92. The lowest was 0.98. And the median was 1.32.


Apex Biotechnology  (TPE:1733) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Apex Biotechnology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=29.90/20.46
=1.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Apex Biotechnology was 1.92. The lowest was 0.98. And the median was 1.32.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Apex Biotechnology Cyclically Adjusted Book per Share Related Terms


Apex Biotechnology Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Cyclically Adjusted Book per Share Chart

Apex Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.21 20.87 20.75 20.63 20.46

Apex Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.63 20.70 20.74 20.71 20.46

TPE:1733 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Apex Biotechnology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apex Biotechnology Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Apex Biotechnology's Cyclically Adjusted PB Ratio falls into.


TPE:1733
81GF Score
Apex Biotechnology Corp TPE:1733
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apex Biotechnology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Apex Biotechnology's adjusted Book Value per Share data for the three months ended in Dec. 2025 was:

Adj_Book= Book Value per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=18.707/324.0540*324.0540
=18.707

Current CPI (Dec. 2025) = 324.0540.

Apex Biotechnology Quarterly Data

Book Value per Share CPI Adj_Book
201603 20.130 238.132 27.393
201606 18.640 241.018 25.062
201609 18.657 241.428 25.042
201612 17.369 241.432 23.313
201703 16.952 243.801 22.532
201706 16.032 244.955 21.209
201709 16.246 246.819 21.330
201712 16.692 246.524 21.942
201803 16.967 249.554 22.032
201806 16.139 251.989 20.755
201809 16.851 252.439 21.631
201812 16.471 251.233 21.245
201903 16.775 254.202 21.385
201906 16.175 256.143 20.463
201909 16.008 256.759 20.204
201912 16.766 256.974 21.143
202003 16.877 258.115 21.188
202006 16.010 257.797 20.125
202009 16.235 260.280 20.213
202012 16.557 260.474 20.598
202103 16.902 264.877 20.678
202106 17.252 271.696 20.577
202109 16.699 274.310 19.727
202112 17.536 278.802 20.382
202203 18.016 287.504 20.306
202206 17.035 296.311 18.630
202209 17.725 296.808 19.352
202212 18.182 296.797 19.852
202303 17.136 301.836 18.397
202306 17.416 305.109 18.497
202309 17.811 307.789 18.752
202312 17.973 306.746 18.987
202403 17.177 312.332 17.822
202406 17.454 314.175 18.003
202409 17.779 315.301 18.273
202412 18.245 315.605 18.733
202503 17.671 319.799 17.906
202506 17.914 322.561 17.997
202509 18.150 324.800 18.108
202512 18.707 324.054 18.707

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of NT$20.46 mean?
Apex Biotechnology (TPE:1733) has a Cyclically Adjusted Book per Share of NT$20.46 as of Dec. 2025. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Apex Biotechnology and its competitors.
Is Apex Biotechnology's Cyclically Adjusted Book per Share too high?
Apex Biotechnology's current Cyclically Adjusted Book per Share is NT$20.46. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Cyclically Adjusted Book per Share compare to VRTX and REGN?
Apex Biotechnology's Cyclically Adjusted Book per Share of NT$20.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Cyclically Adjusted Book per Share is NT$20.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Cyclically Adjusted Book per Share is NT$20.46. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Cyclically Adjusted Book per Share is NT$20.46 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued. The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

  • Cyclically Adjusted Book per Share: NT$20.46
  • GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Apex Biotechnology Business Description

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score

Get the complete analysis for TPE:1733

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.90
Price
NT$30.08
GF Value